Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders

References

• Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149–164.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013 Jan 15;10:8.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23;66(10):1485–1489.
   PubMed Web of Science ®Google Scholar
• Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014 June;20(7):843–847.
   PubMed Web of Science ®Google Scholar
• Beigneux Y, Arnulf I, Guillaume-Jugnot P, et al. Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019;38:101869.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol. 2012;69:1355–1359.
   PubMedGoogle Scholar
• Sepulveda M, Delgado-García G, Blanco Y, et al. Late-onset neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2019;6:e607.
   PubMed Web of Science ®Google Scholar
• Cook LJ, Rose JW, Alvey JS, et al. Collaborative international research in clinical and longitudinal experience study in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2019;6:e583.
   PubMed Web of Science ®Google Scholar
• Chen H-X, Zhang Q, Lian Z-Y, et al. Muscle damage in patients with neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2017;4:e400.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–815.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9. DOI:10.1186/1742-2094-9-14
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 July 14;85(2):177–189.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165–1173.
   PubMed Web of Science ®Google Scholar
• Asseyer S, Schmidt F, Chien C, et al. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2018 July-Sept;4(3):2055217318796684.
   Google Scholar
• Chavarro VS, Mealy MA, Simpson A, et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Dec;3(6):e286.
   PubMed Web of Science ®Google Scholar
• Beekman J, Keisler A, Pedraza O, et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm. 2019;6:e580.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Schliesseit J, Brandt AU, et al. Cognitive impairment in neuromyelitis optica spectrum disorders: a review of clinical and neuroradiological features. Front Neurol. 2019;10:608.
   PubMed Web of Science ®Google Scholar
• Penner IK, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol. 2017 Nov;13(11):662–675.
   PubMed Web of Science ®Google Scholar
• Lennon PVA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112.
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Schollhammer J, Hoepner R, et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol. 2016 Mar;263(3):575–582.
   PubMed Web of Science ®Google Scholar
• Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016 Jan;263(1):25–29.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239–245.
   PubMedGoogle Scholar
• Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 Jan;18(1):113–115.
   PubMed Web of Science ®Google Scholar
• Yamout BI, Beaini S, Zeineddine MM, et al. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Mult Scler. 2017 Aug;23(9):1297–1300.
   PubMed Web of Science ®Google Scholar
• Yoshii F, Moriya Y, Ohnuki T, et al. Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2016 May;7:53–57.
   PubMed Web of Science ®Google Scholar
• Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol. 2014 Jan;261(1):1–16.
   PubMed Web of Science ®Google Scholar
• Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016 Sept;87(9):1005–1015.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008 Apr;4(4):202–214.
   PubMedGoogle Scholar
• Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017 Jan;4(1):e311.
   PubMed Web of Science ®Google Scholar
• Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):137–145.
   PubMed Web of Science ®Google Scholar
• Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015 June;21(7):845–853.
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2018 June;89(6):555–556.
   PubMed Web of Science ®Google Scholar
• Gold SM, Willing A, Leypoldt F, et al. Sex differences in autoimmune disorders of the central nervous system. Semin Immunopathol. 2019 Mar;41(2):177–188.
   PubMed Web of Science ®Google Scholar
• Dos Passos GR, Oliveira LM, da Costa BK, et al. MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol. 2018;9:217.
   PubMed Web of Science ®Google Scholar
• Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015 Feb 2;1:e62. DOI:10.1212/NXI.0000000000000062
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement – frequency, presentation and outcome. J Neuroinflammation. 2016;13:280.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016 Sept 26;13(1):279.
   PubMedGoogle Scholar
• Narayan R, Simpson A, Fritsche K, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018 Oct;25:66–72.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018 May 3;15(1):134.
   PubMedGoogle Scholar
• Cobo-Calvo A, Ayrignac X, Kerschen P, et al. Cranial nerve involvement in patients with MOG antibody-associated disease. Neurol Neuroimmunol Neuroinflamm. 2019 Mar;6(2):e543.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017 Mar;4(2):e322.
   PubMed Web of Science ®Google Scholar
• Matesanz S, Kotch C, Perrone C, et al. Expanding the MOG phenotype: brainstem encephalitis with punctate and curvilinear enhancement. Neurol Neuroimmunol Neuroinflamm. 2019 Nov;6(6). DOI:10.1212/NXI.0000000000000619
   PubMed Web of Science ®Google Scholar
• Vazquez Do Campo R, Stephens A, Marin Collazo IV, et al. MOG antibodies in combined central and peripheral demyelination syndromes. Neurol Neuroimmunol Neuroinflamm. 2018 Nov 5;(6):e503. DOI:10.1212/NXI.0000000000000503
   PubMed Web of Science ®Google Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016 Feb;79(2):206–216.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5:e504.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Kessler RA, Rimler Z, et al. Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm. 2018 July;5(4):e468.
   PubMed Web of Science ®Google Scholar
• Paul F, Murphy O, Pardo S, et al. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs. 2018 Mar;27(3):265–271.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Qiu W, et al.Tocilizumab versus azathioprine in highly relapsing neuromyelitis …. ECTRIMS Online Library. Shi F. ECTRIMS Online Library. 2019 Sept 12; 279439.
   Google Scholar
• Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346–351.
   PubMed Web of Science ®Google Scholar
• Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019 July;6(4):e572.
   PubMed Web of Science ®Google Scholar
• Viswanathan S, Wong AH, Quek AM, et al. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J Neuroimmunol. 2015 May;15(282):92–96.
   Google Scholar
• Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014 Apr;20(4):501–504.
   PubMed Web of Science ®Google Scholar
• Stellmann JP, Krumbholz M, Friede T, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639–647.
   PubMed Web of Science ®Google Scholar
• Qiu W, Kermode AG, Li R, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci. 2015 July;22(7):1178–1182.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang C, Bai P, et al. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. Acta Neurol Belg. 2017 Sept;117(3):695–702.
   PubMed Web of Science ®Google Scholar
• Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011 Aug 16;77(7):659–666.
   PubMed Web of Science ®Google Scholar
• Montcuquet A, Collongues N, Papeix C, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017 Sept;23(10):1377–1384.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014 Mar;71(3):324–330.
   PubMed Web of Science ®Google Scholar
• Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20:1533–1540.
   PubMed Web of Science ®Google Scholar
• Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016 Nov 1;73(11):1342–1348.
   PubMed Web of Science ®Google Scholar
• Durozard P, Rico A, Boutiere C, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol. 2020 Feb;87(2):256–266.
   PubMed Web of Science ®Google Scholar
• Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017 Sept;264(9):2003–2009.
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3701–3706.
   PubMed Web of Science ®Google Scholar
• Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e134.
   PubMed Web of Science ®Google Scholar
• Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014 Apr 15;82(15):1302–1306.
   PubMed Web of Science ®Google Scholar
• Carreon Guarnizo E, Hernandez Clares R, Castillo Trivino T, et al. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurologia. 2019 Mar 27: pii: S0213-4853(19)30033-7. [Epub ahead of print].
   PubMedGoogle Scholar
• Collongues N, Ayme-Dietrich E, Monassier L, et al. Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options. Drugs. 2019 Feb;79(2):125–142.
   PubMed Web of Science ®Google Scholar
• Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013 May;84(5):511–516.
   PubMed Web of Science ®Google Scholar
• Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):918–921.
   PubMed Web of Science ®Google Scholar
• Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol. 2013 Feb;260(2):627–634.
   PubMed Web of Science ®Google Scholar
• Borisow N, Mori M, Kuwabara S, et al. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:888.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Kim S-H, Schmidt F, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2018;24:1737–1742.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89:127–137.
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128–3138.
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019;16:134.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015 July;72(7):756–763.
   PubMed Web of Science ®Google Scholar
• Whittam D, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated demyelination with rituximab: a multinational study of 98 patients (S13.003). Neurology. 2018;90. DOI:10.1212/WNL.0000000000005560
   Web of Science ®Google Scholar
• Li S, Ren H, Xu Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm. 2020 May;7(3). DOI:10.1212/NXI.0000000000000705
   Web of Science ®Google Scholar
• Wildemann B, Jarius S, Schwarz A, et al. Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology. 2017;89:207–209.
   PubMed Web of Science ®Google Scholar
• Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e257.
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018;75:478–487.
   PubMed Web of Science ®Google Scholar
• VielaBio. Viela Bio Receives U.S. FDA breakthrough therapy designation for inebilizumab for treatment of neuromyelitis optica spectrum disorder online press release; 2019 Apr 18. [cited 2019 Nov 4]. Available from: https://ir.vielabio.com/news-releases/news-release-details/viela-bio-receives-us-fda-breakthrough-therapy-designation
   Google Scholar
• Davis J. Eculizumab. Am J Health Syst Pharm. 2008 Sept 1;65(17):1609–1615.
   PubMedGoogle Scholar
• Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373:1032–1039.
   PubMed Web of Science ®Google Scholar
• Moskovich O, Fishelson Z. Quantification of complement C5b-9 binding to cells by flow cytometry. Methods Mol Biol. 2014;1100:103–108.
   PubMedGoogle Scholar
• Sicre de Fontbrune F, Peffault de Latour R. Ten years of clinical experience with eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Semin Hematol. 2018 July;55(3):124–129.
   PubMed Web of Science ®Google Scholar
• Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol. 2017 June;30(3):347–362.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018 Mar;78(3):367–376.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450–1461.
   PubMed Web of Science ®Google Scholar
• Phuan PW, Zhang H, Asavapanumas N, et al. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol. 2013 June;125(6):829–840.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013 June;12(6):554–562.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019 Aug 15;381(7):614–625.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017 July 14;66(27):734–737.
   PubMed Web of Science ®Google Scholar
• Chen D, Gallagher S, Monson NL, et al. Inebilizumab, a B cell-depleting Anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016 Nov 24;5(12). DOI:10.3390/jcm5120107
   PubMed Web of Science ®Google Scholar
• Bennett JL, O’Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015 June;2(3):e104.
   PubMed Web of Science ®Google Scholar
• Sanz I. Rationale for B cell targeting in SLE. Semin Immunopathol. 2014 May;36(3):365–375.
   PubMed Web of Science ®Google Scholar
• Gallagher S, Yusuf I, McCaughtry TM, et al. MEDI-551 treatment effectively depletes B cells and reduces serum titers of autoantibodies in mice transgenic for Sle1 and human CD19. Arthritis Rheumatol. 2016 Apr;68(4):965–976.
   PubMed Web of Science ®Google Scholar
• Marcinnò A, Marnetto F, Valentino P, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;5:e498.
   PubMed Web of Science ®Google Scholar
• Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014 Mar 20;507(7492):366–370.
   PubMed Web of Science ®Google Scholar
• Forsthuber TG, Cimbora DM, Ratchford JN, et al. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018;11:1756286418761697.
   Web of Science ®Google Scholar
• Herbst R, Wang Y, Gallagher S, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335:213–222.
   PubMed Web of Science ®Google Scholar
• Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2019 Feb;25(2):235–245.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Ogura M, Suehiro Y, et al. A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. Int J Hematol. 2019 June;109(6):657–664.
   PubMed Web of Science ®Google Scholar
• Streicher K, Sridhar S, Kuziora M, et al. Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease. Arthritis Rheumatol. 2018 Dec;70(12):2087–2095.
   PubMed Web of Science ®Google Scholar
• Cree B. The N-MOmentum study – a randomised, placebo-controlled, double-blind trial of Inebilizumab for neuromyelitis optica spectrum disorder: randomised controlled period and open-label extension results. Abstract: 139. ECTRIMS Online Library. 2019 Sept 12.
   Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206):1352–1363.
   PubMed Web of Science ®Google Scholar
• Cree BA, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica – ethical and design considerations. Mult Scler. 2016 June;22(7):862–872.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019 Nov 28;381(22):2114–2124.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Greenberg B, Bennett JL, et al. Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): results from SAkuraStar, a double-blind placebo-controlled phase 3 clinical study. ECTRIMS Online Library. 2019.
   Google Scholar
• Bennett JL, Greenberg B, Traboulsee A, et al. Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a double-blind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD). ECTRIMS Online Library. 2019.
   Google Scholar
• Yamamura T. A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD). ECTRIMS Online Library. 2018 Oct 12.
   Google Scholar
• Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019 June;98(25):e15944.
   PubMed Web of Science ®Google Scholar
• Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909.
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530–539.
   PubMed Web of Science ®Google Scholar
• AlexionPharmaceuticals. Positive phase 3 extension data for ULTOMIRIS® (ravulizumab) in patients with paroxysmal nocturnal hemoglobinuria (PNH) presented at European Hematology Association (EHA) Congress; 2019. [cited 2019 Nov 4]. Available from: https://alexionpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/positive-phase-3-extension-data-ultomirisr-ravulizumab-patients
   Google Scholar
• Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008 July;14(7):748–755.
   PubMed Web of Science ®Google Scholar
• Zhang C, Tian DC, Yang CS, et al. Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol. 2017 Aug 1;74(8):1010–1012.
   PubMed Web of Science ®Google Scholar
• Zhang H, Verkman AS. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest. 2013 May;123(5):2306–2316.
   PubMed Web of Science ®Google Scholar
• Katz Sand I, Fabian MT, Telford R, et al. Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2018 Mar;5(2):e441.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Shin K, John G, et al. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 2015 Nov 1;6(4):413–418.
   PubMedGoogle Scholar
• Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2014 June;1(1):e5.
   PubMedGoogle Scholar
• J. Brooks HA, Bose G, Thebault S, et al. Autologous hematopoietic stem cell transplant in patients with severe refractory neuromyelitis optica spectrum disease: the Ottawa experience. ECTRIMS Online Library. 2019.
   Google Scholar
• Cree BAC, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica – ethical and design considerations. Mult Scler. 2016;22:862–872.
   PubMed Web of Science ®Google Scholar
• Rhodes R. A placebo controlled trial for an NMO relapse prevention treatment: ethical considerations. Mult Scler Relat Disord. 2015;4:580–584.
   PubMed Web of Science ®Google Scholar
• Cree BAC. Placebo controlled trials in neuromyelitis optica are needed and ethical. Mult Scler Relat Disord. 2015;4:536–545.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Barron G, Behne JM, et al. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. 2015;84:1805–1815.
   PubMed Web of Science ®Google Scholar
• Levy M. The ethics of placebo controlled clinical trials in NMO – a balance of risks. Mult Scler Relat Disord. 2015 Nov;4(6):512–514.
   PubMed Web of Science ®Google Scholar
• Annovazzi P, Capobianco M, Moiola L, et al. Rituximab in the treatment of neuromyelitis optica: a multicentre Italian observational study. J Neurol. 2016 Sept;263(9):1727–1735.
   PubMed Web of Science ®Google Scholar
• Cabre P, Mejdoubi M, Jeannin S, et al. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol. 2018 Apr;265(4):917–925.
   PubMed Web of Science ®Google Scholar
• Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013 Sept 1;70(9):1110–1117.
   PubMed Web of Science ®Google Scholar
• Cohen M, Romero G, Bas J, et al. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study. J Neurol Sci. 2017 Feb 15;373:335–338.
   PubMed Web of Science ®Google Scholar
• Novi G, Bovis F, Capobianco M, et al. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019 Nov;36:101430.
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015 Sept;72(9):989–995.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim Y, Kim G, et al. Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):486–487.
   PubMed Web of Science ®Google Scholar
• Lebrun C, Cohen M, Rosenthal-Allieri MA, et al. Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders. Neurol Ther. 2018 Dec;7(2):373–383.
   PubMed Web of Science ®Google Scholar
• Ellrichmann G, Bolz J, Peschke M, et al. Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol. 2019 Jan;266(1):57–67.
   PubMed Web of Science ®Google Scholar
• Marcinno A, Marnetto F, Valentino P, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018 Nov;5(6):e498.
   PubMed Web of Science ®Google Scholar
• Tallantyre EC, Whittam DH, Jolles S, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018 May;265(5):1115–1122.
   PubMed Web of Science ®Google Scholar
• Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016 Apr;22(4):511–519.
   PubMed Web of Science ®Google Scholar
• Ellwardt E, Ellwardt L, Bittner S, et al. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm. 2018 July;5(4):e463.
   PubMed Web of Science ®Google Scholar
• Valentino P, Marnetto F, Granieri L, et al. Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study. Neurol Neuroimmunol Neuroinflamm. 2017 Mar;4(2):e317.
   PubMed Web of Science ®Google Scholar
• Yeo T, Probert F, Jurynczyk M, et al. Classifying the antibody-negative NMO syndromes: clinical, imaging, and metabolomic modeling. Neurol Neuroimmunol Neuroinflamm. 2019;6:e626.
   PubMed Web of Science ®Google Scholar
• Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15:89–102.
   PubMed Web of Science ®Google Scholar
• Pandit L, Mustafa S, Nakashima I, et al. MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response. Mult Scler J Exp Transl Clin. 2018;4:205521731878782.
   Google Scholar
• Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3:e225.
   PubMed Web of Science ®Google Scholar
• Kim S-M, Woodhall MR, Kim J-S, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e163.
   PubMed Web of Science ®Google Scholar
• Winklmeier S, Schlüter M, Spadaro M, et al. Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2019;6:625.
   PubMed Web of Science ®Google Scholar
• Kwon YN, Waters PJ, Kim M, et al. Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis. Neurol Neuroimmunol Neuroinflamm. 2019;6. pii: e600.
   PubMed Web of Science ®Google Scholar
• Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019;32:385–394.
   PubMed Web of Science ®Google Scholar
• Spadaro M, Winklmeier S, Beltran E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018 Aug;84(2):315–328.
   PubMed Web of Science ®Google Scholar
• Hoftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020 Feb 11. DOI:10.1007/s00401-020-02132-y
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, d’Indy H, Ruiz A, et al. Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: a multicenter cross-sectional study. Neurol Neuroimmunol Neuroinflamm. 2020 Mar;7(2). DOI:10.1212/NXI.0000000000000649
   PubMed Web of Science ®Google Scholar
• Gehr S, Kaiser T, Kreutz R, et al. Suggestions for improving the design of clinical trials in multiple sclerosis – results of a systematic analysis of completed phase III trials. Epma J. 2019;10:425–436.
   PubMed Web of Science ®Google Scholar
• Schmidt F, Zimmermann H, Mikolajczak J, et al. Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2017;11:45–50.
   PubMed Web of Science ®Google Scholar
• D’Souza M, Papadopoulou A, Levy M, et al. Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: results of an international survey. Mult Scler Relat Disord. 2020 Feb;29(41):102027.
   Google Scholar
• Kessler RA, Mealy MA, Levy M. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Oct;3(5):e269.
   PubMed Web of Science ®Google Scholar
• Ventura RE, Kister I, Chung S, et al. Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflamm. 2016 June;3(3):e224.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm. 2017 May;4(3):e334.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Nakashima I. Foveal thinning in neuromyelitis optica: a sign of retinal astrocytopathy? Neurol Neuroimmunol Neuroinflamm. 2017 May;4(3):e347.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Outteryck O, Knier B, et al. Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. J Neuroinflammation. 2019 July 25;16(1):154.
   PubMedGoogle Scholar
• Oertel FC, Havla J, Roca-Fernandez A, et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1259–1265.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Zimmermann H, Paul F, et al. Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. Epma J. 2018 Mar;9(1):21–33.
   PubMed Web of Science ®Google Scholar
• Havla J, Kumpfel T, Schinner R, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017 Jan;264(1):139–151.
   PubMed Web of Science ®Google Scholar
• Jeong IH, Kim HJ, Kim NH, et al. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. J Neurol. 2016 July;263(7):1343–1348.
   PubMed Web of Science ®Google Scholar
• Bennett JL, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015 May;21(6):678–688.
   PubMed Web of Science ®Google Scholar
• Streitberger KJ, Fehlner A, Pache F, et al. Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. Eur Radiol. 2017 May;27(5):2206–2215.
   PubMed Web of Science ®Google Scholar
• Warabi Y, Takahashi T, Isozaki E. Progressive cerebral atrophy in neuromyelitis optica. Mult Scler. 2015 Dec;21(14):1872–1875.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee EJ, Kim S, et al. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm. 2020 May;7(3). DOI:10.1212/NXI.0000000000000708
   Web of Science ®Google Scholar
• Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019 Sept 24;93(13):e1299–e1311.
   PubMed Web of Science ®Google Scholar
• Florez-Grau G, Zubizarreta I, Cabezon R, et al. Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials. Front Immunol. 2018;9:1169.
   PubMed Web of Science ®Google Scholar
• Zubizarreta I, Florez-Grau G, Vila G, et al. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8463–8470.
   PubMed Web of Science ®Google Scholar
• Steinman L, Bar-Or A, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: part I. Neurol Neuroimmunol Neuroinflamm. 2016 Oct;3(5):e276.
   PubMedGoogle Scholar
• Bar-Or A, Steinman L, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: part II. Neurol Neuroimmunol Neuroinflamm. 2016 Oct;3(5):e277.
   PubMedGoogle Scholar